Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × asciminib × Breast × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 22 Myeloid 18 Other solid neoplasm 3 Lymphoid 3 Gastrointestinal 1 CNS 1 Breast 1

Conditions

HER2+ Metastatic Breast Cancer 1

Interventions

Trastuzumab 612 Paclitaxel 604 Cyclophosphamide 559 Docetaxel 495 Capecitabine 431 Letrozole 359 Carboplatin 342 Fulvestrant 333 Doxorubicin 294 Tamoxifen 257 pembrolizumab 237 Anastrozole 216 Epirubicin 213 exemestane 204 Radiotherapy 196 Bevacizumab 194 Gemcitabine 188 pertuzumab 187 Vinorelbine 175 Lapatinib 164 palbociclib 158 130-nm albumin-bound paclitaxel 149 Albumin-Bound Paclitaxel 141 Magnetic Resonance Spectroscopy 137 eribulin 129 Exercise 129 Taxes 116 Fluorouracil 114 Cisplatin 104 Everolimus 103

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07136428 2025-12-19

ASCENdANT

Duke University

Phase 1/2 Not yet recruiting

HER2+ Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡